Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Inhibikase Therapeutics Inc (NQ: IKT ) 1.360 -0.040 (-2.86%) Streaming Delayed Price Updated: 3:59 PM EDT, May 9, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 34,612 Open 1.390 Bid (Size) 1.350 (51) Ask (Size) 1.370 (8) Prev. Close 1.400 Today's Range 1.350 - 1.390 52wk Range 0.7900 - 4.351 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension Today 8:00 EDT From Inhibikase Therapeutics Via GlobeNewswire Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session April 22, 2024 Via Benzinga Performance YTD +2.12% +2.12% 1 Month -38.46% -38.46% 3 Month -50.00% -50.00% 6 Month +27.10% +27.10% 1 Year -62.95% -62.95% More News Read More 12 Health Care Stocks Moving In Monday's Intraday Session April 22, 2024 Via Benzinga Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs April 18, 2024 From Inhibikase Therapeutics Via GlobeNewswire Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension April 03, 2024 From Inhibikase Therapeutics Via GlobeNewswire IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q4 2023 March 27, 2024 Via InvestorPlace Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity March 27, 2024 From Inhibikase Therapeutics Via GlobeNewswire Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders March 07, 2024 From Inhibikase Therapeutics Via GlobeNewswire HC Wainwright & Co. Maintains Buy Rating for Inhibikase Therapeutics: Here's What You Need To Know March 05, 2024 Via Benzinga Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro February 28, 2024 From Inhibikase Therapeutics Via GlobeNewswire Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers February 07, 2024 From Inhibikase Therapeutics Via GlobeNewswire Dr. Milton Werner, CEO of Inhibikase Therapeutics, Inc. is Featured in an Interview With SmallCapsDaily February 05, 2024 Via NewMediaWire Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI January 29, 2024 Via AB Newswire Topics Retirement Exposures Pension Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib January 29, 2024 From Inhibikase Therapeutics Via GlobeNewswire 12 Health Care Stocks Moving In Friday's Intraday Session January 26, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session January 25, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's Intraday Session January 24, 2024 Via Benzinga Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli January 16, 2024 From Inhibikase Therapeutics Via GlobeNewswire Why Dermata Therapeutics Shares Are Trading Higher By Over 57%; Here Are 20 Stocks Moving Premarket January 05, 2024 Via Benzinga Topics Intellectual Property Exposures Intellectual Property Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs December 19, 2023 From Inhibikase Therapeutics Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's Pre-Market Session December 13, 2023 Via Benzinga 12 Health Care Stocks Moving In Tuesday's After-Market Session December 12, 2023 Via Benzinga Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session December 11, 2023 Via Benzinga 12 Health Care Stocks Moving In Monday's After-Market Session December 04, 2023 Via Benzinga Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro December 04, 2023 From Inhibikase Therapeutics Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
